Cover slide: One dose, two Phase 3 trials, two verdicts
Regulatory

One dose, two Phase 3 trials, two verdicts

Bayer took one dose of asundexian into two Phase 3 trials. It lost to apixaban in AF. Last week it won FDA approval in stroke.

Read the article →
Cover slide: Half the exposure is not half the effect
Science

Half the exposure is not half the effect

A fatty breakfast before the dose halves exposure to Merck's oral PCSK9 drug. Once a week, it costs ~1 point of LDL-C lowering (model).

Read →
Cover slide: The first human dose, informed by a QSP model
Regulatory

The first human dose, informed by a QSP model

FDA's June 2026 draft guidance describes how a quantitative systems pharmacology model can inform a MABEL-based first-in-human dose, and when a start above MABEL may be justified.

Read →
Regulatory

ICH M15 is final, and every package now follows it

ICH M15 reached Step 4 in January 2026 and FDA published it as final guidance in June 2026. Every package we deliver now follows its framework.

Read →
Studio

pmxstudio.ai is open for projects

The studio now takes on population PK, exposure-response, MIDD and submission-package work, each on a fixed price and a fixed timeline.

Read →
Regulatory

Project Optimus and the case for early exposure-response

Project Optimus has moved dose optimization from a late-stage afterthought to an early-development expectation.

Read →
Method

How the work is split between agents and the modeler

A pharmacometric analysis is a sequence of distinct tasks, and each one rewards a different kind of automation.

Read →

Follow the notes on LinkedIn

Two short notes a week, each with its slides and its sources.